biotech / news / / MarketScreener
Novo Nordisk aims to slash the time it takes to bring new drugs to market by up to two-thirds.
Novo Nordisk aims to cut new drug launch timelines by up to two-thirds using AI.
KEY POINTS
- AI is now deeply integrated in Novo Nordisk’s India operations, especially in Bengaluru.
- The Bengaluru centre plays a pivotal role in nearly all global drug launches, including the new oral obesity pill.
- Novo Nordisk has revised its hiring targets downward, focusing on AI-driven efficiency over headcount.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →